CG Oncology Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Indicates management contract or compensatory plan.
- This certification is deemed not filed for purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
† Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601 of Regulation S-K because it is both not material and is the type that the registrant treats as private or confidential.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
CG ONCOLOGY, INC.
/s/ Arthur Kuan
Arthur KuanChairman and Chief Executive Officer
Date: March 26, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Arthur Kuan | Chairman and Chief Executive Officer | March 26, 2024 |
| Arthur Kuan | (principal executive officer) | |
| /s/ Corleen Roche | Chief Financial Officer | March 26, 2024 |
| Corleen Roche | (principal financial and accounting officer) | |
| /s/ Susan Graf | Director | March 26, 2024 |
| Susan Graf | ||
| /s/ Brian Liu, M.D. | Director | March 26, 2024 |
| Brian Liu, M.D. | ||
| /s/ James J. Mulé, IPh.D. | Director | March 26, 2024 |
| James J. Mulé, IPh.D. | ||
| /s/ Leonard Post, Ph.D. | Director | March 26, 2024 |
| Leonard Post, Ph.D. | ||
| /s Simone Song | Director | March 26, 2024 |
| Simone Song | ||
| /s/ Victor Tong, Jr. | Director | March 26, 2024 |
| Victor Tong, Jr. | ||
CG ONCOLOGY, INC.
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 | F-4 |
| Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit for the years ended December 31, 2023 and 2022 | F-5 |
| Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-6 |
| Notes to Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.